文献速递淋巴瘤

套细胞淋巴瘤的基因突变与特征:系统综述与荟萃分析

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2020-01-01

该系统综述检索3个数据库并纳入32篇文章,用贝叶斯多元回归模型对2127例套细胞淋巴瘤(MCL)患者进行患者水平荟萃分析。诊断或基线肿瘤/骨髓样本中ATM突变率最高(43.5%),其次为TP53(26.8%)、CDKN2A(23.9%)和CCND1(20.2%)。从基线到疾病进展突变状态发生变化,突变频率差异>5%的基因应纳入靶向二代测序panel。

要点

  • 基线ATM突变率43.5%,TP53 26.8%,CDKN2A 23.9%,CCND1 20.2%。
  • IGH异常38.4%、MYC异常20.8%,主要通过细胞遗传学方法检测。
  • 从基线到疾病进展突变状态发生变化,突变频率差异>5%的基因应纳入靶向测序panel。

核心结论

  • MCL基线突变谱以ATM(43.5%)、TP53(26.8%)、CDKN2A(23.9%)、CCND1(20.2%)最常见,从基线到疾病进展突变状态发生变化,突变频率变化最大的基因应纳入靶向二代测序panel,并需分析系列样本。

研究设计与样本

  • 系统综述检索3个数据库,纳入32篇描述MCL患者突变的文章,并用贝叶斯多元回归模型对2127例MCL患者进行患者水平数据的荟萃分析。

主要发现

  • 诊断或基线肿瘤或骨髓样本中,ATM突变频率最高(43.5%),其次为TP53(26.8%)、CDKN2A(23.9%)、CCND1(20.2%)。
  • IGH异常(38.4%)和MYC异常(20.8%)主要通过细胞遗传学方法检测。
  • 其他常见基线突变为NSD2(15.0%)、KMT2A(8.9%)、S1PR1(8.6%)、CARD11(8.5%)。
  • 从基线样本到疾病进展样本,突变状态发生变化;突变频率差异>5%的基因包括TP53、ATM、KMT2A、MAP3K14、BTK、TRAF2、CHD2、TLR2、ARID2、RIMS2、NOTCH2、TET2、SPEN、NSD2、CARD11、CCND1、SP140、CDKN2A和S1PR1。

临床怎么用

  • 作者认为突变频率变化最大的基因应纳入未来研究的靶向二代测序panel。
  • 作者指出这些发现强调需要在MCL中分析系列样本。
  • 作者认为MCL常见突变的患者水平数据为推进MCL精准医学倡议中的分子变异性提供了额外证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect pathogenesis, prognosis, and therapeutic response. In this systematic review, we searched 3 databases and selected 32 articles that described mutations in MCL patients. We then conducted a meta-analysis using a Bayesian multiregression model to analyze patient-level data in 2127 MCL patients, including prevalence of mutations. In tumor or bone marrow samples taken at diagnosis or baseline, ATM was the most frequently mutated gene (43.5%) followed by TP53 (26.8%), CDKN2A (23.9%), and CCND1 (20.2%). Aberrations were also detected in IGH (38.4%) and MYC (20.8%), primarily through cytogenetic methods. Other common baseline mutations were NSD2 (15.0%), KMT2A (8.9%), S1PR1 (8.6%), and CARD11 (8.5%). Our data also show a change in mutational status from baseline samples to samples at disease progression and present mutations of interest in MCL that should be considered for future analysis. The genes with the highest mutational frequency difference (>5%) are TP53, ATM, KMT2A, MAP3K14, BTK, TRAF2, CHD2, TLR2, ARID2, RIMS2, NOTCH2, TET2, SPEN, NSD2, CARD11, CCND1, SP140, CDKN2A, and S1PR1. These findings provide a summary of the mutational landscape of MCL. The genes with the highest change in mutation frequency should be included in targeted next-generation sequencing panels for future studies. These findings also highlight the need for analysis of serial samples in MCL. Patient-level data of prevalent mutations in MCL provide additional evidence emphasizing molecular variability in advancing precision medicine initiatives in MCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hill HA, Qi X, Jain P, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020. PMID: 32598477. doi:10.1182/bloodadvances.2019001350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。